Listening to "December 2023 – Eur Urol Oncology highlights" at buzzsprout.com/2220728/142769… European Urology Oncology European Association of Urology (EAU) Ashish M. Kamat, MD, MBBS Riccardo Campi Cathy Elena Castro Alicia Morgans, MD, MPH Ploussard Guillaume Jeremy Teoh Laurence Albiges Declan Murphy

The #MCCRWorkshop enables peer #mentoring and #CareerDevelopment for early-career #oncology professionals. Apply now to gain access to mentors and develop protocols ready for submission. ⏲️ Deadline: 1 February 2024. ow.ly/m7TG50QtYnF EORTC AACR #CancerResearch

Proud of Gustave Roussy GU group celebrating 20th anniversary #GU24 🎂 Thrilled to contribute to 20years of advances in GU cancers care ! Missing Pierre Blanchard, MD Alberto Bossi Christophe Massard

Still time to apply 👉 #ESMOPreceptorship on Metastatic #BladderCancer & #KidneyCancer: molecular pathology & diagnosis as contributing factors to heterogeneity, assessment & multidisciplinary tx, advances in tx & novel targets 🔗 ow.ly/FZeH50QBJBl #blcsm #kcsm Laurence Albiges

#ASCO24 abstracts titles are out!!!! brnw.ch/21wJ8kD My top 5 communications in Kidney & Bladder based on the titles: 1. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN

Updated 📢#RenalCellCarcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Assessing mature data for first-line metastatic trials as well as sequencing strategies & new agents such as belzutifan. ow.ly/nZA050RP77l #kcsm @silke_gillessen

Renal cancer highlights #ASCO24 KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) ⬆️ in kidney injury and is immune suppressive(Treg), Already used for nephrotox. Robert Motzer MD presented compelling data form adjuvant ipi/nivo #AACR24. A 2nd +ve study would be meaningful?

Top 5 Must See Kidney and Bladder Data Sumanta K. Pal, MD, FASCO #ASCO24 ASCO Laurence Albiges Brian Rini, MD Robert Motzer MD Shilpa Gupta Genitourinary Cancer Research Team @CityofHope City of Hope Click Here for the Data Links: oncologytube.com/monty-pal-md-t…

Don't miss tomorrow's Rapid Oral Abstract Session - Friday 8:30 @Montypal will present the Preliminary results of P1 study monotherapy of DFF332: promising safety profile & have been indications of clinical activity ASCO #ASCO24 Laurence Albiges 👉meetings.asco.org/abstracts-pres…

Exciting preliminary data from Phase I/Ib study of HIF2α inhibitor DFF332 in pts w/ advanced ccRCC presented by my dear friend Sumanta K. Pal, MD, FASCO at #ASCO24: promising safety profile, indications of clinical activity, and dose-proportional modulation of EPO. ASCO Laurence Albiges OncoAlert

Circulating kidney injury molecule-1 may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma. #ASCO24 #kcsm Laurence Albiges urologytimes.com/view/kim-1-eme…

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by Wenxin (Vincent) Xu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with Laurence Albiges spotifyanchor-web.app.link/e/9vRDmeiGeKb

#BreakingNews‌ Our 2023 IF is now 8.3 ! So proud of our amazing team Laurence Albiges Ashish M. Kamat, MD, MBBS Riccardo Campi Elena Castro Jeremy Teoh Alicia Morgans, MD, MPH Renu Eapen Ploussard Guillaume Cathy European Urology Oncology

Please join Laurence Albiges Guillermo de Velasco #JensBedkeMD & myself at #ESMO24 for a discussion of #kidneycancer that will span topics of #adjuvant & #metastatic dz tx. We have worked hard to incorporate discussion around data presented just a day earlier- incl perspectives on #TiNivo2,

Today is a very special day for patients with RCC : CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs) Data presented at ESMO - Eur. Oncology and published in NEJM

In his Keynote Lecture at #ELCC25, Benjamin Besse discusses when ‘less is more,’ describing different de-escalation strategies to balance the efficacy versus toxicity of #CancerTreatment, particularly #immunotherapy Read more in the #ESMODailyReporter🔗 ow.ly/sEeh50VqnHY

Day 1 ESMO - Eur. Oncology #Preceptorship in Metastatic #urothelial #RCC #cancer 62 participants from 26 countries selected out of >230 applicants ! Thanks to the faculty for sharing #SOC ESMO - Eur. Oncology #guidelines

🎉 Excited to share that Lisa Derosa will be the Keynote Speaker at 2025 IKCS: Europe! #IKCSEU25 Don't miss her talk on the kidney cancer #microbiome. Register with discount rates till 4/10! kidneycancer.swoogo.com/IKCSEU25

Thanks #ASCO25 for the amazing opportunity to present some of the Gustave Roussy works FabriceAndre Fabrice Barlesi Christophe Massard Benjamin Besse d.planchard Barbara Pistilli Emeline COLOMBA Jordi Remon HollebecqueA JoanaMRibeiro2 Michels Judith lisaderosa and many more !

Among all evaluable patients who received pembrolizumab/lenvatinib, the ORR was 50.6% (95% CI, 42.6%-58.7%), a DCR of 82.3% (95% CI, 75.4%-87.9%), and a CBR of 71.5% (95% CI, 63.8%-78.4%). #kicsm #KCRS2025 | KidneyCAN Laurence Albiges cancernetwork.com/view/pembroliz…